Anagenics Limited

AN1

AU0000198095

Personal Products

Market Closed - Australian S.E. Other stock markets 03:51:44 17/07/2024 BST			5-day change	1st Jan Change
0.008 ^AUD	0.00%		0.00%	-57.89%

05-24	Anagenics Signs Midkine Antibody Licencing Deal with Roquefort Therapeutics	MT
03-08	Anagenics Appoints CEO	MT

Cellmid Limited : Appendix 4C Quarterly report

January 29, 2013 at 07:09 am

MarketScreener.com By

ASX ANNOUNCEMENT

NOTES TO APPENDIX 4C

SYDNEY, Tuesday, 29 January 2013: Cellmid Limited (ASX: CDY) provides the following comments in relation to the attached Appendix 4C form:

Latest news about Anagenics Limited

Anagenics Signs Midkine Antibody Licencing Deal with Roquefort Therapeutics	05-24	MT
Anagenics Appoints CEO	03-08	MT
Anagenics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-26	CI
Anagenics Completes Placement to Raise AU$1.3 Million	02-07	MT
Anagenics Grows Fiscal H1 Revenue	01-31	MT
Anagenics Acquires Face Medi Group	02/10/23	MT
Anagenics Limited Announces Board Executive Changes	01/10/23	CI
Anagenics Limited completed the acquisition of Face MediGroup.	01/10/23	CI
Anagenics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/08/23	CI
Anagenics Limited agreed to acquire Face MediGroup for AUD 1.3 million.	21/08/23	CI
Anagenics Appoints CEO/Managing Director	29/03/23	MT
Anagenics Limited Appoints Scott Greasley as Managing Director, Effective from 1 April 2023	28/03/23	CI
Anagenics Limited Announces CEO Changes	28/03/23	CI
Anagenics Raises Funds from Institutional Entitlement Offer	16/02/23	MT
Anagenics Raising AU$3.2 Million Via Entitlement Offer	14/02/23	MT
Anagenics Limited Appoints Karen Matthews as Non-Executive Director	13/02/23	CI
Anagenics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	13/02/23	CI
Anagenics Limited acquired Uspa Global Pty. Ltd. from BWX Limited.	08/12/22	CI
Anagenics Approves the Election of Mr. Alexander Beard as A Director	28/11/22	CI
Anagenics Limited Announces Resignation of Dennis Eck as Director	16/10/22	CI
Anagenics Limited Reports Earnings Results for the Full Year Ended June 30, 2022	25/08/22	CI
Anagenics Limited Reports Earnings Results for the Full Year Ended June 30, 2022	25/08/22	CI
Anagenics Grows Fiscal Q4 Revenue 11%	26/07/22	MT
Anagenics Limited Appoints Scott Mitchell Greasley as Director	08/07/22	CI
Anagenics Records 121% Jump in Fiscal Q3 Revenue	28/04/22	MT

Anagenics Limited is an Australia-based health and beauty-tech company. The Company offers a range of clinically validated anti-ageing and wellness products developed in-house or sourced from premium international brands. The Company, through its wholly owned subsidiary Advangen Pty Ltd, develops, manufactures and markets anti-aging products globally, with its FGF5 inhibitor hair health and hair growth products sold worldwide. The flagship anti-aging hair care range, marketed as evolis, Advangen Jo-Ju and Lexilis brands, is sold in Japan, the United States of America and Australia. The Companyâs subsidiary is BLC Cosmetics Pty Limited, which is the distributor of international and local skin care and wellbeing brands.

Sector

Personal Products

Calendar

27/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Personal Products

	1st Jan change	Capi.
ANAGENICS LIMITED	-57.89%	2.48M
PROCTER & GAMBLE COMPANY	+15.84%	394B
UNILEVER PLC	+17.39%	142B
COLGATE-PALMOLIVE COMPANY	+24.80%	79.91B
HINDUSTAN UNILEVER LIMITED	+0.99%	75.63B
ESTEE LAUDER	-30.97%	36.21B
KENVUE INC.	-14.44%	34.95B
BEIERSDORF	+1.03%	32.96B
ESSITY AB	+13.04%	18.46B
GODREJ CONSUMER PRODUCTS LIMITED	+28.43%	17.78B

Other Personal Products

Anagenics Limited

Equities

AN1

AU0000198095

Personal Products

Cellmid Limited : Appendix 4C Quarterly report

Latest news about Anagenics Limited

Chart Anagenics Limited

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Personal Products